Year All20262025202420232022202120202019 Aug 06, 2026 Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium Aug 04, 2026 Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile Jul 21, 2026 Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 Jul 16, 2026 Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition Jun 11, 2026 Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting May 27, 2026 Harmony Biosciences to Participate in Upcoming Investor Conferences May 07, 2026 Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities Apr 23, 2026 Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 Apr 16, 2026 Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting Apr 14, 2026 Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
Aug 04, 2026 Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
Jul 16, 2026 Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
May 07, 2026 Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
Apr 16, 2026 Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
